Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Rani Therapeutics Holdings Inc

Healthcare US RANI

0.8295USD
-0.0691(7.69%)

Last update at 2026-06-05T20:15:00Z

Day Range

0.810.90
LowHigh

52 Week Range

1.828.75
LowHigh

Fundamentals

  • Previous Close 0.90
  • Market Cap236.19M
  • Volume843420
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-62.73500M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 2.72M
  • Diluted EPS TTM-1.29

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -63.27400M -53.04700M -16.66800M -26.58700M
Minority interest -32.75600M 44.76M - -
Net income -63.34400M -53.08800M -16.70300M -26.59700M
Selling general administrative 26.84M 27.83M 4.96M 3.46M
Selling and marketing expenses - - - -
Gross profit - 2.72M 0.46M 0.98M
Reconciled depreciation 0.55M 0.50M 0.59M 0.56M
Ebit -63.45100M -51.59900M -16.54400M -27.06500M
Ebitda -62.20300M -51.51000M -15.89200M -26.07800M
Depreciation and amortization 1.25M 0.09M 0.65M 0.99M
Non operating income net other 1.25M - - -
Operating income -63.45100M -51.59900M -16.54400M -27.06500M
Other operating expenses 63.45M 54.32M 17.01M 28.04M
Interest expense 1.07M 0.47M 0.12M 0.01000M
Tax provision 0.07M 0.04M 0.04M 0.00000M
Interest income 1.25M 0.09M 0.06M 0.42M
Net interest income 0.18M -0.37700M -0.06100M 0.41M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.07M 0.04M 0.04M 0.01000M
Total revenue 0.00000M 2.72M 0.46M 0.98M
Total operating expenses 63.45M 54.32M 17.01M 28.04M
Cost of revenue - - - -
Total other income expense net 0.18M -1.44800M -0.12400M 0.48M
Discontinued operations - - - -
Net income from continuing ops -63.34400M -53.08800M -16.70300M -26.58700M
Net income applicable to common shares -61.17600M -8.33100M -16.70300M -26.58700M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 57.92M 108.03M 124.21M 79.42M 23.02M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.31M 1.94M 2.14M 0.17M 0.16M
Total liab 32.47M 34.02M 2.64M 192.75M 119.66M
Total stockholder equity 12.87M 36.85M 47.41M -113.33900M -96.63600M
Deferred long term liab - - - - -
Other current liab 1.73M 2.35M 1.56M 0.69M 3.12M
Common stock 0.00500M 0.00500M 0.00500M 0.66M 0.66M
Capital stock 0.00500M 0.00500M 0.00500M 0.66M 0.66M
Retained earnings -72.88900M -38.91900M -8.33100M -114.00300M -97.30000M
Other liab - - - - -
Good will - - - - -
Other assets 0.00000M - - - 1.62M
Cash 6.36M 27.01M 117.45M 73.06M 16.54M
Cash and equivalents - - - - -
Total current liabilities 7.99M 4.82M 2.64M 5.31M 3.50M
Current deferred revenue - - - 2.72M 0.18M
Net debt 23.73M 3.21M -117.45300M -69.28700M -16.53600M
Short term debt 5.62M 1.01M - 1.36M -
Short long term debt 4.90M - - 1.36M -
Short long term debt total 30.10M 30.21M - 3.77M -
Other stockholder equity 85.76M 75.84M 55.74M - -
Property plant equipment - 6.04M 4.61M 4.47M 4.45M
Total current assets 50.55M 100.92M 119.59M 74.94M 16.94M
Long term investments - - - - -
Net tangible assets - 36.85M 47.41M -113.33900M -96.63600M
Short term investments 42.67M 71.47M - - -
Net receivables 0.20M - - 1.72M 0.25M
Long term debt 24.48M 29.15M - 2.41M -
Inventory - - - - -
Accounts payable 0.65M 1.46M 1.08M 0.54M 0.20M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - 37.15M - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.01200M -0.07300M -124.20700M - -
Additional paid in capital - - - - -
Common stock total equity - 0.00500M - - -
Preferred stock total equity - - - - -
Retained earnings total equity - -38.91900M - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.55M 1.06M - - 1.62M
Deferred long term asset charges - - - - -
Non current assets total 7.37M 7.10M 4.61M 4.47M 6.08M
Capital lease obligations 0.72M 1.06M - - -
Long term debt total - 29.15M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -70.81700M -0.50600M -1.20000M -1.53200M
Change to liabilities 0.77M -2.17400M 3.47M -0.45000M
Total cashflows from investing activities -72.43600M -0.50600M -1.20000M -1.53200M
Net borrowings 29.57M -4.56800M 4.04M 4.04M
Total cash from financing activities 29.00M 77.15M 72.68M 0.85M
Change to operating activities - -1.25500M -2.42700M 0.29M
Net income -63.34400M -53.08800M -16.70300M -26.58700M
Change in cash -89.94600M 44.40M 56.52M -26.94700M
Begin period cash flow 117.45M 73.06M 16.54M 43.48M
End period cash flow 27.51M 117.45M 73.06M 16.54M
Total cash from operating activities -46.51500M -32.24500M -14.96000M -26.26700M
Issuance of capital stock 0.00000M 79.97M 68.49M 0.00000M
Depreciation 0.55M 0.50M 0.59M 0.56M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock 0.27M - - -
Other cashflows from financing activities 28.73M 8.07M 72.68M 0.85M
Change to netincome 15.78M -20.98200M 0.11M -0.08100M
Capital expenditures 1.62M 0.51M 1.20M 1.58M
Change receivables - - - -
Cash flows other operating 0.51M - - -
Exchange rate changes - - - -
Cash and cash equivalents changes -89.94600M - - -
Change in working capital 0.51M -3.42900M 1.04M -0.16300M
Stock based compensation 15.78M 22.59M - -
Other non cash items -0.01000M 0.11M 0.11M -0.08100M
Free cash flow -48.13400M -32.75100M -16.16000M -27.84800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RANI
Rani Therapeutics Holdings Inc		 -0.0691 7.69% 0.83 - - 313.17 21.72 84.28 -1.4229
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Rani Therapeutics Holdings Inc

2051 Ringwood Avenue, San Jose, CA, United States, 95131

Key Executives

Name Title Year Born
Mr. Mir A. Imran Exec. Chairman 1956
Mr. Talat Imran CEO & Director 1981
Mr. Svai S. Sanford Chief Financial Officer 1970
Dr. Mir Hashim Chief Scientific Officer 1960
Mr. Eric Groen Gen. Counsel NA
Ms. Bella Vazquez VP of HR NA
Mr. Mir A. Imran Executive Chairman 1956
Mr. Talat Imran CEO & Director 1982
Mr. Eric Groen General Counsel 1971
Ms. Bella Vazquez Vice President of Human Resources NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions